Desmopressin vs Vasopressin
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, Desmopressin or Vasopressin?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between Desmopressin and Vasopressin?
Vasopressin activates both V1 (vasoconstriction) and V2 (antidiuretic) receptors, making it useful as a vasopressor; desmopressin's engineered V2 selectivity eliminates the vasopressor effect, making it safer for chronic antidiuretic use but useless for shock.
Evidence Comparison
Both: FDA approved. Vasopressin: endogenous hormone, approved as vasopressor for distributive shock (VASST trial). Desmopressin: V2-selective analog, approved for diabetes insipidus and nocturnal enuresis. Both have robust clinical evidence for their distinct indications.
Evidence Context Favoring Desmopressin
Chronic antidiuretic therapy (diabetes insipidus, enuresis) where V1-mediated vasoconstriction is unwanted.
Evidence Context Favoring Vasopressin
Acute vasopressor support in distributive shock where V1-mediated vasoconstriction is the therapeutic goal.
Side-by-Side Snapshot
| Evidence grade | Desmopressin: Level A Vasopressin: Level A |
|---|---|
| Research status | Desmopressin: FDA Approved Vasopressin: FDA Approved |
| Primary category | Desmopressin: Healing & Recovery Vasopressin: Healing & Recovery |
| Cited studies | Desmopressin: 3 Vasopressin: 3 |